All Effectiveness Bank analyses to date of documents related to use and problem use of illegal drugs starting with the analyses most recently added or updated, totalling today 815 documents.
Click blue titles to view full text in a new window
Use the selectors at the bottom to turn to the next page in the list of documents
Crits-Christoph P., Ring-Kurtz S., Hamilton J.L. et al.
Journal of Substance Abuse Treatment: 2012, p. 301–309.
Evidence that an earlier study feeding back client progress to counsellors did not find improved outcomes because data was aggregated across a caseload rather than identifying individuals doing poorly and recommending remedial actions. After remedying these deficits, a new system significantly improved mental health and reduced substance use.
STUDY 2018 HTM file
Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings – what is required to achieve the WHO’s HCV elimination targets?
Ward Z., Platt L., Sweeney S. et al.
Addiction: 2018, 113, p. 1727–1738.
What would it take for the UK to meet the World Health Organization’s target of a 90% reduction in hepatitis C by 2030? According to projections in three diverse areas, current levels of harm reduction services are averting a great deal of transmission, and adding only moderate rates of treatment for hepatitis C would put Britain on course to achieve the elimination target.
Glynn T.R., van den Berg J.J.
Transgender Health: 2017, 2(1), p. 45–59.
Part review, part ‘call to action’, the featured paper highlights the lack of awareness of evidence-based interventions for transgender people, and advocates for ‘culturally-sensitive’ approaches embedded in both general and specialised substance use programmes.
DOCUMENT 2017 HTM file
Drug misuse prevention: targeted interventions
National Institute for Health and Care Excellence and Public Health England.
[UK] National Institute for Health and Care Excellence, 2017
From the UK’s health and social care advisory body, evidence-based guidance on how to improve the delivery of substance use prevention to at-risk children, young people, and adults.
Scottish Government, 2018
Taking a public health and human rights-based approach, the 2018 strategy from Scotland strives to improve citizens’ lives by preventing and reducing the harms of drinking and drug use.
McDonald R., Strang J.
Addiction: 2016, 111, p. 1177–1187.
How confident can we be that take-home naloxone programmes are effective without the ‘gold standard’ randomised trial? Judged against nine criteria for establishing the presumption of causality, evidence that the provision of naloxone reduces overdose-related deaths among opioid users.
COLLECTION 2018 HTM file
The client–therapist relationship
‘Collections’ are customised Effectiveness Bank searches not available via the standard options in the search pages. At the heart of addiction treatment lies client–therapist relationships, across psychotherapy a stronger influence on how well clients do than the type of therapy.
McAuley A., Munro A., Taylor A.
International Journal of Drug Policy: 2018, 58, p. 46–54.
Important implications for overdose prevention policy and practice in Scotland and the UK from this qualitative study which provides the first detailed insights into how people who inject drugs experience administering naloxone rescue kits.
REVIEW 2009 HTM file
Mindfulness meditation for substance use disorders: a systematic review
Zgierska A., Rabago D., Chawla N. et al.
Substance Abuse: 2009, 30(4), p. 266–294.
Increasingly popular, variants of mindfulness meditation are among the ‘third wave’ of behavioural therapies allying Western and Eastern traditions. This first review of their application to addiction delivered a ‘promising but unproven’ verdict, one replicated in a later review based on more studies.
REVIEW 2018 HTM file
Drug consumption rooms: an overview of provision and evidence
European Monitoring Centre for Drugs and Drug Addiction
European Monitoring Centre for Drugs and Drug Addiction, 2018
Refreshing its overview of the use of drug consumption rooms, the European Union’s drug misuse monitoring centre says the evidence still contradicts concerns that such facilities encourage drug use, delay treatment entry, or aggravate problems arising from local drug markets – finding instead that both the users and the community stand to benefit.
Select search results pagePREVIOUS | NEXT 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82